Zealand Pharma A/S - ESG Rating & Company Profile powered by AI
The ESG score includes seventeen United Nations SDGs including: 'Zero Hunger', 'Reduced Inequalities' and 'Life on Land'. Check the end of this webpage for potential risks for Zealand Pharma A/S based on industry, location and size. Alternative corporations in the rating industry group for Zealand Pharma A/S are displayed.
Zealand Pharma A/S in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.1; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 18 | Pacific Biosciences of California Inc | 8.2 | High |
| 18 | Valneva SE | 8.2 | High |
| 36 | Zealand Pharma A/S | 8.1 | High |
| 36 | Adcock Ingram Holdings Ltd | 8.1 | High |
| 36 | Alkem Laboratories Ltd | 8.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Zealand Pharma A/S have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Zealand Pharma A/S disclose current and historical energy intensity?
Sign up for free to unlockDoes Zealand Pharma A/S report the average age of the workforce?
Sign up for free to unlockDoes Zealand Pharma A/S reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Zealand Pharma A/S disclose its ethnicity pay gap?
Sign up for free to unlockDoes Zealand Pharma A/S disclose cybersecurity risks?
Sign up for free to unlockDoes Zealand Pharma A/S offer flexible work?
Sign up for free to unlockDoes Zealand Pharma A/S have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Zealand Pharma A/S disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Zealand Pharma A/S conduct supply chain audits?
Sign up for free to unlockDoes Zealand Pharma A/S disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Zealand Pharma A/S conduct 360 degree staff reviews?
Sign up for free to unlockDoes Zealand Pharma A/S disclose the individual responsible for D&I?
Sign up for free to unlockDoes Zealand Pharma A/S disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Zealand Pharma A/S disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Zealand Pharma A/S disclose water use targets?
Sign up for free to unlockDoes Zealand Pharma A/S have careers partnerships with academic institutions?
Sign up for free to unlockDid Zealand Pharma A/S have a product recall in the last two years?
Sign up for free to unlockDoes Zealand Pharma A/S disclose incidents of discrimination?
Sign up for free to unlockDoes Zealand Pharma A/S allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Zealand Pharma A/S issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Zealand Pharma A/S disclose parental leave metrics?
Sign up for free to unlockDoes Zealand Pharma A/S disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Zealand Pharma A/S disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Zealand Pharma A/S disclose the pay ratio of women to men?
Sign up for free to unlockDoes Zealand Pharma A/S support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Zealand Pharma A/S disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Zealand Pharma A/S reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Zealand Pharma A/S involved in embryonic stem cell research?
Sign up for free to unlockDoes Zealand Pharma A/S disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Zealand Pharma A/S disclose its waste policy?
Sign up for free to unlockDoes Zealand Pharma A/S report according to TCFD requirements?
Sign up for free to unlockDoes Zealand Pharma A/S disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Zealand Pharma A/S disclose energy use targets?
Sign up for free to unlockDoes Zealand Pharma A/S disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Zealand Pharma A/S have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Zealand Pharma A/S
These potential risks are based on the size, segment and geographies of the company.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.